An Update on ISoP Special Interest Groups (SIGs)

McCarthy, Deirdre M.; Bahri, Priya; Barnes, Joanne; Delumeau, Jean-Christophe; Edwards, Brian; Harrison‐Woolrych, Mira

doi:10.1007/s40264-017-0603-5

Cited by 7 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A first update on the CommSIG activities was published in 2018 [ 12 ]. This article further updates what the CommSIG has achieved to date, gives a complete overview of the key messages arising from the sessions at ISoP meetings as a basis for continuing progress, and presents the CommSIG’s directions for the 2020s in addressing current challenges.…”

Section: The International Society Of Pharmacovigilance Special Inter...mentioning

confidence: 99%

Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance

et al. 2023

Self Cite

View full text Add to dashboard Cite

Section: The International Society Of Pharmacovigilance Special Inter...mentioning

confidence: 99%

Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance

et al. 2023

Self Cite

View full text Add to dashboard Cite

“…As preventing medication errors requires innovative strategies and sharing of knowledge and experience, ISoP established the Special Interest Group on Medication Errors (SIG-ME) in 2017 under the leadership of Dr. Brian Edwards and Dr. Angela Caro. The SIG acts as a forum for the exchange of knowledge, technology, and experience between countries and regions, particularly through the organization of workshops and symposiums [2]. Now well-established, SIG-ME has developed training courses and promoted new research and dissemination of best practices to strengthen PV systems to support members involved in implementing best medication safety practices around the world.…”

Section: The Isop Special Interest Group On Medication Errors (Sig-me)mentioning

confidence: 99%

Medication Errors Special Interest Group of the International Society of Pharmacovigilance and the Trends in International Collaboration for Patient Safety

Elhawary

Rostom

Edwards³

et al. 2022

Drug Saf

Self Cite

View full text Add to dashboard Cite

“…The safety profile of benznidazole is far from optimal. Frequent adverse reactions are relatively mild, including skin reactions, gastrointestinal complaints, and neurological symptoms, while 3% of cases develop severe reactions, such as peripheral neuropathy, toxic hepatitis, Lyell syndrome, anaphylactic reaction, and Stevens-Johnson syndrome [8]. The adverse reactions can lead to treatment discontinuity, and patients under benznidazole treatment need careful medical follow-up.…”

Section: Introductionmentioning

confidence: 99%

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole

et al. 2020

View full text Add to dashboard Cite

Approximately 300,000 persons in the United States (US) are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease, but less than 1% are estimated to have received antiparasitic treatment. Benznidazole was approved by the US Food and Drug Administration (FDA) for treatment of T. cruzi infection in 2017 and commercialized in May 2018. This paper analyzes factors that affect access to benznidazole following commercialization and suggests directions for future actions to expand access. We applied an access framework to identify barriers, facilitators, and key actors that influence the ability of people with Chagas disease to receive appropriate treatment with benznidazole. Data were collected from the published literature, key informants, and commercial databases. We found that the mean number of persons who obtained benznidazole increased from just under 5 when distributed by the CDC to 13 per month after the commercial launch (from May 2018 to February 2019). Nine key barriers to access were identified: lack of multi-sector coordination, failure of health care providers to use a specific order form, lack of an emergency delivery system, high medical costs for uninsured patients, narrow indications for use of benznidazole, lack of treatment guidelines, limited number of qualified treaters, difficulties for patients to make medical appointments, and inadequate evaluation by providers to determine eligibility for treatment. Our analysis shows that access to benznidazole is still limited after FDA approval. We suggest six areas for strategic action for the pharmaceutical company that markets benznidazole and its allied private foundation to expand access to benznidazole in the US. In addition, we recommend expanding the existing researcher-clinician network by including government agencies, companies and others. This paper's approach could be applied to access programs for benznidazole in other countries or for other health products that target neglected populations throughout the world.

show abstract

An Update on ISoP Special Interest Groups (SIGs)

Cited by 7 publications

References 3 publications

Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance

Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance

Medication Errors Special Interest Group of the International Society of Pharmacovigilance and the Trends in International Collaboration for Patient Safety

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole

Contact Info

Product

Resources

About